INCYIncyte
$119.69+29% 1Y
$119.69
$90.3052 weeks$129.88
The business
How INCY's business earns
Incyte keeps 10% of every revenue dollar as operating profit, against −62% for the median Biotechnology name.
10%
Operating margin · Biotechnology median −62% · 12 months to Sep 30, 2026
- Cash conversion
- 2.35×
Cash conversion · 1.13× a year ago · operating cash flow divided by operating profit after tax
- Share count, year on year
- +0.90%
Share count, year on year · within 1% of a year ago
- R&D as % of revenue
- 57%
R&D as % of revenue
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2020 | −9.9% |
| FY2021 | 20% |
| FY2022 | 17% |
| FY2023 | 17% |
| FY2024 | 1.5% |
| FY2025 | 29% |
Details›
- Gross margin12 months to Sep 30, 2026
- 93%
- Operating margin12 months to Sep 30, 2026
- 10%
- Net margin12 months to Sep 30, 2026
- 6.7%
- R&D as % of revenue
- 57%
- Revenue, trailing twelve months
- $6.01B
- Net income, trailing twelve months
- $403M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from INCY and who it buys from, as the companies report it.
18%of revenue comes from customer C, the largest of 4 disclosed customers
no supplier on file
INCY
Customer C18%
Customer D15%
Customer A11%
Customer B9.0%
Customerswho buys
- Customer C18%
Share of revenue · FY2025 10-K
- Customer D15%
Share of revenue · FY2025 10-K
- Customer A11%
Share of revenue · FY2025 10-K
- Customer B9.0%
Share of revenue · FY2025 10-K
Supplierswho it buys from
None disclosed.
Biotechnology
The closest names by size in the same industry